ClinicalTrials.gg
RecruitingNCT03318406Updated Jan 28, 2025

Post-Market BTVA Registry

An observational study in Emphysema or COPD, sponsored by Uptake Medical Technology, Inc.. Recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Uptake Medical Technology, Inc. · Observational

From the registry’s dates

  • Started Mar 2018; still recruiting 8 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Bronchoscopic thermal vapor ablation using Uptake Medical Technology Inc.'s InterVapor System is indicated for treatment of patients with heterogeneous upper lobe emphysema. This study is a retrospective and prospective, observational, multi-center, post-market registry of patients prescribed InterVapor. The primary objective of the Registry is to describe the long-term impact of InterVapor treatment on patient quality of life (QOL) in a real-world setting. After InterVapor treatment, patients will be followed for 5 years as per the standard of care and safety and efficacy data (quality of life, pulmonary function, exercise capacity) collected as part of the registry.

Read the detailed description

The BTVA Registry will enroll up to 300 patients with upper lobe predominant emphysema that are being treated with BTVA at sites located in the EU and other select geographies. Patients will be followed as per standard of care and the registry will collect follow-up data for five years following treatment. The follow up data collected will include pulmonary function measurements (spirometry, body plethysmography, and diffusing capacity for carbon monoxide), exercise capacity (six minute walk test), imaging findings (chest x-ray and CT), and a quality of life questionnaire (SGRQ-C). All serious and non-serious adverse events will also be collected for the duration of the study in order to assess safety. Serious adverse events will be adjudicated by an independent medical monitor in order to establish relatedness to the InterVapor device and procedure.

Descriptive statistics will be used to summarize all safety and effectiveness data. There is no predefined hypothesis regarding the magnitude of effectiveness of InterVapor or the incidence of specific safety outcomes.

Monitoring of the registry study will be undertaken as a continuous process to ensure that high-quality data are obtained and to ensure compliance with registry procedures.

02

Conditions studied

  • Emphysema or COPD

Keywords

  • registry
  • vapor ablation
  • InterVapor
  • BTVA
03

In context

Emphysema

382 studies on the registry are indexed under Emphysema; 59 are open to participants now.

This study's planned enrollment of 300 is above the median of 131 across 111 observational studies indexed under Emphysema.

Browse Emphysema studies →

Lead sponsor

Uptake Medical Technology, Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with upper lobe predominant emphysema being evaluated for possible InterVapor treatment will be considered for enrollment in the Registry

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients will have heterogeneous emphysema, as evidenced by high-resolution computed tomography (HRCT) demonstrating a heterogeneity index > or equal to 1.2 in at least one segment to be treated
  2. Patients must be > or equal to 18 years of age
  3. Patients are required to provide prior to inclusion in the Registry

Exclusion criteria

Exclusion Criteria:

  1. \< 20% predicted
  2. DLCO \< 20% predicted
  3. Inability to walk > 140 meters in 6 minutes (6MWD) following optimized medical management
  4. Unstable (any of the following):

    1. > 3 COPD related hospitalizations requiring antibiotics in past 12 months
    2. COPD related hospitalization in past 3 months
    3. daily use of systemic , i.e. > 5 mg prednisolone
  5. Concomitant illnesses or medications that would pose a significant increased risk for complications following treatment with InterVapor. Examples of particular relevance include: immune system disorders, medications of clinical relevance, bleeding disorders and unstable cardiovascular conditions, history of asthma or alpha-1 antitrypsin deficiency
  6. Newly prescribed morphine derivatives within the last 4 weeks
  7. Pregnant or breastfeeding
  8. Highly diseased lower lobes (tissue to air ratio of \<11%)
  9. Bacterial infection or symptoms indicative of active infection (i.e., fever, elevated white blood cell count)
  10. Presence of single large bulla (defined as > 1/3 volume of lobe) or a paraseptal distribution of emphysema in the treated lobe
  11. Recent respiratory infections or COPD exacerbation in preceding 6 weeks -
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
300 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • BTVA treated patients

    Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment

    Device: Bronchoscopic Thermal Vapor Ablation

Interventions

  • DeviceBronchoscopic Thermal Vapor Ablation

    Bronchoscopic vapor delivery to airway segment(s) targeted for treatment

    Also known as: BTVA, InterVapor

06

What researchers measure

Primary outcomes

  1. Change in Quality of Life

    Change in Quality of Life score as assessed by the SGRQ-C questionnaire

    Time frame: Baseline to 24 months

Secondary outcomes

  1. Serious Adverse Events

    procedure and device related serious adverse events, major medical complications

    Time frame: 6 and 12 months

  2. Change in FEV1

    Change in Forced Expired Volume in 1 second

    Time frame: Baseline to 12 months

  3. Change in FVC

    Change in Forced Vital Capacity

    Time frame: Baseline to 12 months

  4. Change in TLC

    Change in Total Lung Capacity

    Time frame: Baseline to 12 months

  5. Change in RV

    Change in Residual Volume

    Time frame: Baseline to 12 months

  6. Change in DLCO

    Change in Diffusing capacity of the lung for carbon monoxide

    Time frame: Baseline to 12 months

  7. Exercise Tolerance

    Change in six minute walk distance

    Time frame: Baseline to 12 months

  8. Lung volume reduction

    change in lung volume assessed by CT

    Time frame: Baseline to 6 months

07

Study locations

17 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03318406
Lead sponsor
Uptake Medical Technology, Inc.
Responsible party
Sponsor
First posted
Oct 23, 2017
Start date
Mar 22, 2018
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Jan 28, 2025

Study contacts

Jennifer Idris
Contact
jidris@broncus.com
+1-408-391-0098
Felix Herth, MD, PhD
principal investigator · Thoraxklinik University of Heidelberg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion